NASDAQ:AARD Aardvark Therapeutics Q3 2026 Earnings Results & Report $1.52 -0.01 (-0.33%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Aardvark Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.88 versus the -$0.69 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Aardvark Therapeutics EPS ResultsActual EPS-$0.88Consensus EPS -$0.69Beat/MissMissed by -$0.19One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersAardvark Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aardvark Therapeutics Q3 2026 Earnings FAQ Did Aardvark Therapeutics beat earnings estimates for Q3 2026? Aardvark Therapeutics (NASDAQ:AARD) reported earnings of -$0.88 per share for Q3 2026, missing the consensus estimate of -$0.69. The report was announced on Friday, November 13, 2026. Aardvark Therapeutics Earnings HeadlinesAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates4 hours ago | globenewswire.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Stock Has Consensus Price Target of $11.56November 12 at 2:15 AM | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 13 at 1:00 AM | Profits Run (Ad)Aardvark Therapeutics consensus price target decreased 26.96% to $10.65November 2, 2026 | msn.comAardvark Therapeutics, Inc. (AARD)October 27, 2026 | finance.yahoo.comHC Wainwright Adjusts PT on Aardvark Therapeutics to $2 From $4, Maintains Neutral RatingOctober 26, 2026 | marketscreener.comMSee More Aardvark Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aardvark Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aardvark Therapeutics and other key companies, straight to your email. Email Address About Aardvark TherapeuticsAardvark Therapeutics (NASDAQ:AARD) is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity. Aardvark’s work centers on developing treatments for metabolic conditions with limited therapeutic options. Its investigational candidates are still in development and are not approved medicines.View Aardvark Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
